CY1119905T1 - Ρετροϊικα οχηματα τροποποιημενης ζωνης πολυπουρινης - Google Patents
Ρετροϊικα οχηματα τροποποιημενης ζωνης πολυπουρινηςInfo
- Publication number
- CY1119905T1 CY1119905T1 CY20181100167T CY181100167T CY1119905T1 CY 1119905 T1 CY1119905 T1 CY 1119905T1 CY 20181100167 T CY20181100167 T CY 20181100167T CY 181100167 T CY181100167 T CY 181100167T CY 1119905 T1 CY1119905 T1 CY 1119905T1
- Authority
- CY
- Cyprus
- Prior art keywords
- nucleotide sequence
- retroviral
- interest
- nucleic acids
- particles
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15041—Use of virus, viral particle or viral elements as a vector
- C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
- C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/108—Plasmid DNA episomal vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/24—Vectors characterised by the absence of particular element, e.g. selectable marker, viral origin of replication
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Virology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Artificial Filaments (AREA)
- Polyurethanes Or Polyureas (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Παρέχεται μια κασέτα μεταφοράς ρετροϊκού οχήματος με ανεπάρκεια ενσωμάτωσης που στερείται λειτουργικής ζώνης πολυπουρίνης (ΡΡΤ). Επίσης παρέχονται απομονωμένα νουκλεϊνικά οξέα που περιλαμβάνουν μια ετερόλογη νουκλεοτιδική αλληλουχία, μια ή δύο ρετροϊικές τελικές επαναλαμβανόμενες αλληλουχίες (LTRs), ένα σήμα πακεταρίσματος, ένα στοιχείο απόκρισης rev, κι έναν ευκαρυωτικό υποκινητή, όπου το νουκλεϊνικό οξύ στερείται λειτουργικού ΡΡΤ· οχήματα που περιλαμβάνουν τα απομονωμένα νουκλεϊνικά οξέα που αποκαλύπτονται· ανασυνδυασμένα ρετροϊικά σωματίδια και mRNA από αυτά· τυποποιημένες συσκευασίες ρετροϊκού οχήματος· και μεθόδους παραγωγής σωματιδίων οχήματος με ανεπάρκεια ενσωμάτωσης, που επιτυγχάνουν γονιδιακή έκφραση μιας νουκλεοτιδικής αλληλουχίας που παρουσιάζει ενδιαφέρον, και εισαγωγή μιας νουκλεοτιδικής αλληλουχίας που παρουσιάζει ενδιαφέρον στο γονιδίωμα ενός κυττάρου-ξενιστή με σημειακώς εξειδικευμένο ή μη εξειδικευμένο τρόπο.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US711807P | 2007-12-11 | 2007-12-11 | |
PCT/US2008/086409 WO2009076524A2 (en) | 2007-12-11 | 2008-12-11 | Polypurine tract modified retroviral vectors |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1119905T1 true CY1119905T1 (el) | 2018-06-27 |
Family
ID=40756119
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20181100167T CY1119905T1 (el) | 2007-12-11 | 2018-02-09 | Ρετροϊικα οχηματα τροποποιημενης ζωνης πολυπουρινης |
Country Status (16)
Country | Link |
---|---|
US (2) | US9796987B2 (el) |
EP (2) | EP2222861B1 (el) |
JP (2) | JP5749014B2 (el) |
CY (1) | CY1119905T1 (el) |
DK (1) | DK2222861T3 (el) |
ES (1) | ES2664988T3 (el) |
HR (1) | HRP20180184T1 (el) |
HU (1) | HUE036103T2 (el) |
LT (1) | LT2222861T (el) |
NO (1) | NO2222861T3 (el) |
PL (1) | PL2222861T3 (el) |
PT (1) | PT2222861T (el) |
RS (1) | RS56844B1 (el) |
SI (1) | SI2222861T1 (el) |
TR (1) | TR201802323T4 (el) |
WO (1) | WO2009076524A2 (el) |
Families Citing this family (67)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006130855A2 (en) | 2005-06-01 | 2006-12-07 | California Institute Of Technology | Method of targeted gene delivery using viral vectors |
EP2526774A3 (en) | 2006-07-21 | 2013-03-06 | California Institute of Technology | Targeted gene delivery for dendritic cell vaccination |
RS56844B1 (sr) | 2007-12-11 | 2018-04-30 | Univ North Carolina Chapel Hill | Retrovirusni vektori sa modifikovanim polipurinskim nizom |
SI2770061T1 (sl) * | 2009-07-24 | 2019-02-28 | Immune Design Corp. | Neintegrirani lentiviralni vektorji |
JP2014510721A (ja) | 2011-02-15 | 2014-05-01 | イミューン デザイン コーポレイション | ベクターワクチンによる免疫原特異的免疫応答を強化するための方法 |
JP6054942B2 (ja) | 2011-04-08 | 2016-12-27 | イミューン デザイン コーポレイション | 免疫原性組成物、ならびに体液性および細胞性免疫応答を誘発するための該組成物の使用方法 |
US8323662B1 (en) | 2012-03-30 | 2012-12-04 | Immune Design Corp. | Methods useful for generating highly mannosylated pseudotyped lentiviral vector particles comprising a Vpx protein |
US9713635B2 (en) | 2012-03-30 | 2017-07-25 | Immune Design Corp. | Materials and methods for producing improved lentiviral vector particles |
DK2831095T3 (en) | 2012-03-30 | 2019-02-18 | Immune Design Corp | LENTIVIRAL VECTOR PARTICLES WITH IMPROVED TRANSDUCTION EFFICIENCY FOR CELL EXPRESSING DC SIGN |
KR102136433B1 (ko) | 2012-05-16 | 2020-07-22 | 이뮨 디자인 코포레이션 | Hsv-2 백신 |
EP3542816A1 (en) | 2014-02-14 | 2019-09-25 | Immune Design Corp. | Immunotherapy of cancer through combination of local and systemic immune stimulation |
CA2955015A1 (en) | 2014-07-15 | 2016-01-21 | Immune Design Corp. | Prime-boost regimens with a tlr4 agonist adjuvant and a lentiviral vector |
KR101607282B1 (ko) | 2014-12-18 | 2016-03-29 | 충남대학교산학협력단 | 유리형 산화환원조절단백-1 및 이를 함유하는 항염증 약학조성물 |
US10350245B2 (en) | 2015-01-21 | 2019-07-16 | Fred Hutchinson Cancer Research Center | Point-of-care and/or portable platform for gene therapy |
WO2017066570A1 (en) * | 2015-10-15 | 2017-04-20 | The University Of North Carolina At Chapel Hill | Methods and compositions for integration-defective lentiviral vectors |
WO2017068419A2 (en) | 2015-10-22 | 2017-04-27 | Juno Therapeutics Gmbh | Methods, kits, agents and apparatuses for transduction |
AU2016354102B2 (en) | 2015-11-09 | 2022-05-12 | Immune Design Corp. | A retroviral vector for the administration and expression of replicon RNA expressing heterologous nucleic acids |
MX2018005467A (es) | 2015-11-09 | 2018-12-11 | Immune Design Corp | Composiciones que comprenden vectores lentivirales que expresan interleucina-12, y metodos de uso de las mismas. |
JP2019509275A (ja) | 2016-02-23 | 2019-04-04 | イミューン デザイン コーポレイション | マルチゲノムレトロウイルスベクター調製物ならびにそれらを産生および使用するための方法およびシステム |
BR112018070934A2 (pt) | 2016-04-15 | 2019-02-26 | Alpine Immune Sciences, Inc. | proteínas imunomoduladoras variantes ligantes de icos e usos das mesmas |
IL310729A (en) | 2016-04-15 | 2024-04-01 | Alpine Immune Sciences Inc | Immunomodulatory proteins that are variants of CD80 and their uses |
US11471488B2 (en) | 2016-07-28 | 2022-10-18 | Alpine Immune Sciences, Inc. | CD155 variant immunomodulatory proteins and uses thereof |
US11834490B2 (en) | 2016-07-28 | 2023-12-05 | Alpine Immune Sciences, Inc. | CD112 variant immunomodulatory proteins and uses thereof |
CN110088127A (zh) | 2016-07-28 | 2019-08-02 | 高山免疫科学股份有限公司 | Cd155变体免疫调节蛋白及其用途 |
CN109804089A (zh) | 2016-07-29 | 2019-05-24 | 朱诺治疗学股份有限公司 | 用于评估复制型病毒存在或不存在的方法 |
MA46998A (fr) | 2016-12-05 | 2019-10-09 | Juno Therapeutics Inc | Production de cellules modifiées pour une thérapie cellulaire adoptive |
AU2018235838B2 (en) | 2017-03-16 | 2023-12-14 | Alpine Immune Sciences, Inc. | CD80 variant immunomodulatory proteins and uses thereof |
AU2018235835A1 (en) | 2017-03-16 | 2019-09-05 | Alpine Immune Sciences, Inc. | PD-L2 variant immunomodulatory proteins and uses thereof |
CN110831963A (zh) | 2017-03-16 | 2020-02-21 | 高山免疫科学股份有限公司 | Pd-l1变体免疫调节蛋白及其用途 |
CA3070573A1 (en) | 2017-07-29 | 2019-02-07 | Juno Therapeutics, Inc. | Reagents for expanding cells expressing recombinant receptors |
BR112020001605A2 (pt) | 2017-08-09 | 2020-08-11 | Juno Therapeutics Inc | métodos para produzir composições de células geneticamente modificadas e composições relacionadas |
CA3077509A1 (en) | 2017-10-10 | 2019-04-18 | Alpine Immune Sciences, Inc. | Ctla-4 variant immunomodulatory proteins and uses thereof |
JP7282760B2 (ja) | 2017-10-18 | 2023-05-29 | アルパイン イミューン サイエンシズ インコーポレイテッド | バリアントicosリガンド免疫調節タンパク質ならびに関連する組成物および方法 |
EP3704230A1 (en) | 2017-11-01 | 2020-09-09 | Juno Therapeutics, Inc. | Process for generating therapeutic compositions of engineered cells |
CA3080509A1 (en) | 2017-11-01 | 2019-05-09 | Juno Therapeutics, Inc. | Process for producing a t cell composition |
CN112041430A (zh) | 2017-12-08 | 2020-12-04 | 朱诺治疗学股份有限公司 | 用于培养细胞的无血清培养基配制品及其使用方法 |
BR112020013236A2 (pt) | 2018-01-03 | 2020-12-01 | Alpine Immune Sciences, Inc. | proteínas imunomoduladoras de múltiplos domínios e métodos de seu uso |
EP3746569A1 (en) | 2018-01-31 | 2020-12-09 | Juno Therapeutics, Inc. | Methods and reagents for assessing the presence or absence of replication competent virus |
WO2019241758A1 (en) | 2018-06-15 | 2019-12-19 | Alpine Immune Sciences, Inc. | Pd-1 variant immunomodulatory proteins and uses thereof |
AU2019345151A1 (en) | 2018-09-19 | 2021-04-29 | Alpine Immune Sciences, Inc. | Methods and uses of variant CD80 fusion proteins and related constructs |
BR112021008289A2 (pt) | 2018-11-01 | 2021-10-26 | Juno Therapeutics, Inc. | Métodos para tratamento utilizando receptores de antígeno quimérico específico para antígeno de maturação de célula b |
CN113271963A (zh) | 2018-11-16 | 2021-08-17 | 朱诺治疗学股份有限公司 | 给予工程化t细胞以治疗b细胞恶性肿瘤的方法 |
WO2020113188A2 (en) | 2018-11-30 | 2020-06-04 | Juno Therapeutics, Inc. | Methods for dosing and treatment of b cell malignancies in adoptive cell therapy |
EP3887394A2 (en) | 2018-11-30 | 2021-10-06 | Alpine Immune Sciences, Inc. | Cd86 variant immunomodulatory proteins and uses thereof |
SG11202105502RA (en) | 2018-11-30 | 2021-06-29 | Juno Therapeutics Inc | Methods for treatment using adoptive cell therapy |
KR20220035032A (ko) | 2019-04-17 | 2022-03-21 | 알파인 이뮨 사이언시즈, 인코포레이티드 | 변이체 icos 리간드(icosl) 융합 단백질의 방법 및 용도 |
US20220228101A1 (en) | 2019-06-07 | 2022-07-21 | Juno Therapeutics, Inc. | Automated t cell culture |
WO2020252218A1 (en) | 2019-06-12 | 2020-12-17 | Juno Therapeutics, Inc. | Combination therapy of a cell-mediated cytotoxic therapy and an inhibitor of a prosurvival bcl2 family protein |
WO2021035194A1 (en) | 2019-08-22 | 2021-02-25 | Juno Therapeutics, Inc. | Combination therapy of a t cell therapy and an enhancer of zeste homolog 2 (ezh2) inhibitor and related methods |
US20220412954A1 (en) | 2019-11-05 | 2022-12-29 | Juno Therapeutics, Inc. | Methods of determining attributes of therapeutic t cell compositions |
MX2022006715A (es) | 2019-12-06 | 2022-09-23 | Juno Therapeutics Inc | Metodos relacionados con toxicidad y respuesta asociada con terapia celular para tratar neoplasias malignas de celulas b. |
BR112022014501A2 (pt) | 2020-01-24 | 2022-09-20 | Juno Therapeutics Inc | Métodos para dosagem e tratamento de linfoma folicular e linfoma de zona marginal em terapia celular adotiva |
EP4097218A1 (en) | 2020-01-28 | 2022-12-07 | Juno Therapeutics, Inc. | Methods for t cell transduction |
US20230149462A1 (en) | 2020-04-10 | 2023-05-18 | Juno Therapeutics, Inc. | Methods and uses related to cell therapy engineered with a chimeric antigen receptor targeting b-cell maturation antigen |
CN115812077A (zh) | 2020-05-08 | 2023-03-17 | 高山免疫科学股份有限公司 | April和baff抑制性免疫调节蛋白及其使用方法 |
US20230178239A1 (en) | 2020-05-13 | 2023-06-08 | Juno Therapeutics, Inc. | Methods of identifying features associated with clinical response and uses thereof |
WO2022133030A1 (en) | 2020-12-16 | 2022-06-23 | Juno Therapeutics, Inc. | Combination therapy of a cell therapy and a bcl2 inhibitor |
CN117321200A (zh) | 2021-03-22 | 2023-12-29 | 朱诺治疗学股份有限公司 | 评估病毒载体颗粒效力的方法 |
KR20230159851A (ko) | 2021-03-22 | 2023-11-22 | 주노 쎄러퓨티크스 인코퍼레이티드 | 치료 세포 조성물의 효력을 결정하는 방법 |
BR112023019847A2 (pt) | 2021-03-29 | 2023-11-07 | Juno Therapeutics Inc | Métodos para dosagem e tratamento com uma combinação de uma terapia com inibidor de ponto de verificação e uma terapia com célula t car |
CA3216795A1 (en) | 2021-05-07 | 2022-11-10 | Alpine Immune Sciences, Inc. | Methods of dosing and treatment with a taci-fc fusion immunomodulatory protein |
WO2023114949A1 (en) | 2021-12-16 | 2023-06-22 | Sana Biotechnology, Inc. | Methods and systems of particle production |
WO2023147515A1 (en) | 2022-01-28 | 2023-08-03 | Juno Therapeutics, Inc. | Methods of manufacturing cellular compositions |
WO2023172883A1 (en) | 2022-03-07 | 2023-09-14 | Alpine Immune Sciences, Inc. | Immunomodulatory proteins of variant cd80 polypeptides, cell therapies thereof and related methods and uses |
WO2023230548A1 (en) | 2022-05-25 | 2023-11-30 | Celgene Corporation | Method for predicting response to a t cell therapy |
WO2023250400A1 (en) | 2022-06-22 | 2023-12-28 | Juno Therapeutics, Inc. | Treatment methods for second line therapy of cd19-targeted car t cells |
WO2024077018A2 (en) | 2022-10-04 | 2024-04-11 | Alpine Immune Sciences, Inc. | Methods and uses of taci-fc fusion immunomodulatory protein |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5861161A (en) | 1994-09-07 | 1999-01-19 | Universite De Montreal | Chimeric proteins comprising a Vpr/Vpx virion incorporation domain for targeting into HIV-1 or HIV-2 virions |
DE69626681T2 (de) * | 1995-11-28 | 2004-02-12 | The Johns Hopkins University School Of Medicine | Konditionell-replizierende virale vektoren und ihre verwendung. |
WO2001030965A2 (en) | 1999-10-28 | 2001-05-03 | The Board Of Trustees Of The Leland Stanford Junior University | Methods of in vivo gene transfer using a sleeping beauty transposon system |
US6673567B2 (en) | 2000-03-23 | 2004-01-06 | E. I. Du Pont De Nemours And Company | Method of determination of gene function |
WO2002042482A2 (en) * | 2000-11-27 | 2002-05-30 | Chiron Corporation | Functional lentiviral vector from an mlv-based backbone |
AU2003260769A1 (en) * | 2002-09-03 | 2004-03-29 | Oxford Biomedica (Uk) Limited | Retroviral vector and stable packaging cell lines |
US7220578B2 (en) * | 2002-11-27 | 2007-05-22 | Tal Kafri | Single LTR lentivirus vector |
WO2005023313A1 (en) * | 2003-09-09 | 2005-03-17 | Virxsys Corporation | Lentivirus vector-based approaches for generating an immune response to hiv humans |
GB0325379D0 (en) | 2003-10-30 | 2003-12-03 | Oxford Biomedica Ltd | Vectors |
US20060019393A1 (en) * | 2003-12-04 | 2006-01-26 | Cannon Paula M | Minimal lentiviral vector system |
JP2007054069A (ja) * | 2005-08-24 | 2007-03-08 | Medizinische Hochschule Hannover | 自己不活性化レトロウイルスベクター |
EP1757703A3 (en) | 2005-08-24 | 2007-12-05 | Medizinische Hochschule Hannover | Self-inactivating retroviral vector |
RS56844B1 (sr) | 2007-12-11 | 2018-04-30 | Univ North Carolina Chapel Hill | Retrovirusni vektori sa modifikovanim polipurinskim nizom |
-
2008
- 2008-12-11 RS RS20180107A patent/RS56844B1/sr unknown
- 2008-12-11 EP EP08859393.4A patent/EP2222861B1/en active Active
- 2008-12-11 PL PL08859393T patent/PL2222861T3/pl unknown
- 2008-12-11 EP EP17204678.1A patent/EP3342872A1/en not_active Withdrawn
- 2008-12-11 NO NO08859393A patent/NO2222861T3/no unknown
- 2008-12-11 SI SI200831929T patent/SI2222861T1/en unknown
- 2008-12-11 PT PT88593934T patent/PT2222861T/pt unknown
- 2008-12-11 ES ES08859393.4T patent/ES2664988T3/es active Active
- 2008-12-11 DK DK08859393.4T patent/DK2222861T3/en active
- 2008-12-11 TR TR2018/02323T patent/TR201802323T4/tr unknown
- 2008-12-11 HU HUE08859393A patent/HUE036103T2/hu unknown
- 2008-12-11 LT LTEP08859393.4T patent/LT2222861T/lt unknown
- 2008-12-11 US US12/747,076 patent/US9796987B2/en active Active
- 2008-12-11 JP JP2010538155A patent/JP5749014B2/ja active Active
- 2008-12-11 WO PCT/US2008/086409 patent/WO2009076524A2/en active Application Filing
-
2015
- 2015-01-28 JP JP2015013974A patent/JP6001702B2/ja active Active
-
2017
- 2017-10-23 US US15/790,530 patent/US10017785B2/en active Active
-
2018
- 2018-01-31 HR HRP20180184TT patent/HRP20180184T1/hr unknown
- 2018-02-09 CY CY20181100167T patent/CY1119905T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
EP2222861A4 (en) | 2011-12-28 |
TR201802323T4 (tr) | 2018-03-21 |
WO2009076524A2 (en) | 2009-06-18 |
HUE036103T2 (hu) | 2018-06-28 |
PT2222861T (pt) | 2018-02-16 |
US20100323403A1 (en) | 2010-12-23 |
JP2015119715A (ja) | 2015-07-02 |
EP2222861A2 (en) | 2010-09-01 |
PL2222861T3 (pl) | 2018-04-30 |
US10017785B2 (en) | 2018-07-10 |
ES2664988T3 (es) | 2018-04-24 |
EP3342872A1 (en) | 2018-07-04 |
WO2009076524A3 (en) | 2009-09-11 |
JP2011505835A (ja) | 2011-03-03 |
LT2222861T (lt) | 2018-03-26 |
JP5749014B2 (ja) | 2015-07-15 |
RS56844B1 (sr) | 2018-04-30 |
SI2222861T1 (en) | 2018-04-30 |
NO2222861T3 (el) | 2018-05-05 |
DK2222861T3 (en) | 2018-02-05 |
US9796987B2 (en) | 2017-10-24 |
EP2222861B1 (en) | 2017-12-06 |
US20180119170A1 (en) | 2018-05-03 |
JP6001702B2 (ja) | 2016-10-05 |
HRP20180184T1 (hr) | 2018-04-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1119905T1 (el) | Ρετροϊικα οχηματα τροποποιημενης ζωνης πολυπουρινης | |
Liu et al. | Sensitive and rapid detection of microRNAs using hairpin probes-mediated exponential isothermal amplification | |
Dai et al. | RNA-binding protein HuR autoregulates its expression by promoting alternative polyadenylation site usage | |
Marquitz et al. | The Epstein–Barr Virus BART microRNAs target the pro-apoptotic protein Bim | |
Huenten et al. | p53-regulated networks of protein, mRNA, miRNA, and lncRNA expression revealed by integrated pulsed stable isotope labeling with amino acids in cell culture (pSILAC) and next generation sequencing (NGS) analyses | |
CY1119331T1 (el) | Ισοθερμικη ενισχυση νουκλεικων οξεων | |
ES2909073T3 (es) | Producción biotecnológica escalable de moléculas de adn monocatenario de secuencia y longitud definidas | |
Frohn et al. | Dicer-dependent and-independent Argonaute2 protein interaction networks in mammalian cells | |
DE602004021496D1 (de) | Für eine heterologe nitroreduktase kodierender onkolytischer herpes simplex virus | |
JP2018534937A5 (el) | ||
SG194745A1 (en) | Nucleic acid encoding reactions | |
WO2010141433A3 (en) | Virus discovery by sequencing and assembly of virus-derived sirnas, mirnas, pirnas | |
CY1114483T1 (el) | Νεα ρυθμιστικα στοιχεια | |
Mazda et al. | E-cadherin is transcriptionally activated via suppression of ZEB1 transcriptional repressor by small RNA-mediated gene silencing | |
Yao et al. | An avian retrovirus uses canonical expression and processing mechanisms to generate viral microRNA | |
US9029137B2 (en) | ACP promoter | |
WO2007095201A3 (en) | Pseudotyped retroviral vectors and methods of use thereof | |
Eamens et al. | Vectors and methods for hairpin RNA and artificial microRNA-mediated gene silencing in plants | |
Sigl et al. | Development of a multipurpose GATEWAY-based lentiviral tetracycline-regulated conditional RNAi system (GLTR) | |
CN101899434A (zh) | 一种可连接多片段的重叠延伸pcr方法 | |
WO2011003690A8 (en) | Highly sensitive rapid isothermal method for the detection of point mutations and snps, a set of primers and a kit therefor | |
Ghaderi et al. | Construction of an eGFP expression plasmid under control of T7 promoter and IRES sequence for assay of T7 RNA polymerase activity in mammalian cell lines | |
Vopálenský et al. | Firefly luciferase gene contains a cryptic promoter | |
Kim et al. | The determination of importance of sequences neighboring the Psi sequence in lentiviral vector transduction and packaging efficiency | |
BR112022002307A2 (pt) | Oligonucleotídeos quimicamente modificados que têm como alvo snps |